Core Points - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [3] - The company will report its third quarter 2025 financial results on November 6, 2025 [1] - A conference call will be held on the same day at 8:30 a.m. ET to discuss the financial results and provide a business update [2] Company Overview - Altimmune's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD), and obesity [3] - The company is committed to developing innovative treatments for significant health issues related to liver and cardiometabolic conditions [3]

Summary of the Conference Call on Altimmune and Pemvidutide Company Overview - **Company**: Altimmune - **Product**: Pemvidutide - **Focus**: Clinical-stage biotechnology company developing treatments for metabolic dysfunction-associated steatohepatitis (MASH) Key Industry Insights - **Event**: HC Wainwright Virtual Liver Disease Conference - **Context**: The conference combined discussions on viral hepatitis, MASH, and liver cancer, highlighting the growing interest in liver disease therapeutics Core Points and Arguments 1. **Pemvidutide Mechanism**: Pemvidutide is a dual GLP-1/glucagon receptor agonist, designed to treat multiple components of MASH through direct liver effects and metabolic benefits [2][3] 2. **Clinical Data**: The 24-week study showed class-leading MASH resolution of approximately 59% of patients, with expectations for even better results at the upcoming 48-week data readout [5][8] 3. **Weight Loss and Liver Fat**: At the 1.8 mg dose, patients experienced over 6% weight loss, with about 50% normalizing liver fat [6][8] 4. **Tolerability Profile**: Pemvidutide demonstrated the lowest rates of adverse event discontinuations among incretins, with only 1% overall discontinuation due to adverse events [16][17] 5. **Regulatory Strategy**: The company is preparing for an end of phase 2 meeting with the FDA, focusing on the design of the phase 3 program and the potential use of non-invasive tests (NITs) as surrogates for biopsies [13][15] 6. **Market Opportunity**: MASH represents a significant commercial opportunity, targeting patients across various fibrosis stages (F2 to F4) [22][23] 7. **Competitive Positioning**: Altimmune believes that pemvidutide's dual mechanism provides a unique advantage over other therapies that typically focus on either metabolic or liver effects [20][25] Additional Important Insights - **Upcoming Milestones**: The company anticipates presenting 48-week data and having an end of phase 2 meeting with the FDA in the fourth quarter, which are critical for advancing to phase 3 trials [26] - **Combination Therapies**: There is a trend in the industry towards combination therapies for MASH, and pemvidutide's ability to address both liver and metabolic issues in a single molecule positions it favorably [24][25] - **Investor Sentiment**: The management team expressed confidence in pemvidutide's differentiation and readiness for phase 3, emphasizing the importance of upcoming data and regulatory discussions for investor interest [26] This summary encapsulates the key points discussed during the conference call, focusing on Altimmune's pemvidutide and its implications for the MASH treatment landscape.

Core Insights - Altimmune, Inc. is set to present 24-week efficacy and safety data from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) at The Liver Meeting 2025 [1][4] - The company anticipates announcing 48-week data in Q4 2025, indicating ongoing development and potential for further insights into the treatment's effectiveness [4] Presentation Details - The late-breaking presentations will focus on the recent 24-week data readout from the IMPACT Phase 2b trial [4] - A poster will feature AI-based analyses of liver fibrosis reduction, showcasing innovative approaches in the study [1][8] Study Overview - The IMPACT trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive weekly subcutaneous pemvidutide doses of either 1.2 mg, 1.8 mg, or placebo for 24 weeks [5] - Key efficacy endpoints include MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH at 24 weeks, with secondary endpoints focusing on weight loss and non-invasive tests of fibrosis [5] About Pemvidutide - Pemvidutide is a novel peptide-based dual receptor agonist targeting GLP-1 and glucagon receptors, aimed at treating MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) [6] - The FDA has granted Fast Track designations for pemvidutide in both MASH and AUD, highlighting significant unmet medical needs in these areas [6] Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead product candidate [9]

Core Viewpoint - ALT5 Sigma Corporation will participate in the A.G.P. Digital Assets & Technology Showcase on October 8, 2025, highlighting its role in the digital asset treasury sector [1] Company Participation - The presentation will feature Jonathan Hugh, Chief Financial Officer of ALT5 Sigma, indicating the company's commitment to engaging with industry stakeholders [1] - Other notable participants include Zak Folkman, Co-Founder of World Liberty Financial, and Matt Morgan, Advisor to World Liberty Financial, showcasing a collaborative approach within the digital asset space [1]

Core Points - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][3] Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction, despite prior inflated expectations [4] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [5]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for alleged inflated expectations regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune failed to achieve statistical significance in the primary endpoint of fibrosis reduction in the trial, despite previously optimistic projections [8]. - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61, a decrease of 53.2% in one day [8]. Next Steps - Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4][8].

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the results of its IMPACT Phase 2b MASH trial for Pemvidutide, which led to a significant drop in its stock price following the announcement of trial results that did not meet statistical significance [1][2]. Group 1: Allegations and Impact - The class action is based on a complaint that claims Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025 [1]. - The trial results showed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction, attributed to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of ALT during the specified class period are encouraged to register for the class action by October 6, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Altimmune to contact them to discuss their legal options [1][9] - There is a deadline of October 6, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4][8] Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - The stock price of Altimmune fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - Following the announcement on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61, marking a 53.2% decline in one day [8]. Next Steps - Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to discuss their legal options [1][3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in developing treatments, including Pemvidutide for MASH [3]. - The company faced a setback when it failed to achieve statistical significance in its Phase 2b MASH trial, leading to inflated expectations prior to the announcement [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [4]. Group 3: Legal Actions - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [5].